Divine Aleru, Microbiome Medicine Research Coordinator

This review examines how microbial dysbiosis in the gut contributes to systemic autoimmune diseases like type 1 diabetes, MS, RA, and SLE. It emphasizes microbial influences on immune responses and suggests potential microbiome-based therapies.

This review discusses the role of gut microbiota dysbiosis in IBD, its interaction with intestinal barriers, and the potential of microbiota-targeted therapies like antibiotics, probiotics, and FMT in treating IBD.

This review focuses on the genetic and epigenetic factors that contribute to Inflammatory Bowel Disease (IBD), highlighting key genes and microbiome interactions, and their role in disease pathogenesis and treatment response.

This review explores immunomodulatory therapies for IBD, focusing on their impact on the gut-brain axis. It evaluates conventional and emerging treatments like biologics, FMT, and probiotics, emphasizing their role in improving IBD outcomes and addressing neuropsychiatric symptoms.

The review examines the relationship between gut microbiota, diet, and extrinsic stressors in promoting intestinal inflammation, with implications for managing IBD. It emphasizes the potential benefits of dietary changes and probiotics in restoring gut health and mitigating inflammation.

This review explores the genetic complexities of NOD2 in Crohn’s disease, emphasizing its role in the stricturing phenotype and the need for deeper research into rare variants and their functional impacts.

This review highlights the genetic and environmental factors influencing Crohn’s disease, including the role of NOD2 mutations, smoking, diet, and vitamin D deficiency. It underscores the need for personalized treatment strategies to manage this complex disease.

This review discusses the pathogenesis of osteoporosis in Crohn’s disease, focusing on the role of cytokines, glucocorticoids, and malnutrition. It emphasizes the importance of early detection and treatment strategies to prevent fractures and improve patient outcomes.

This review explores the link between IBD and thromboembolic events, highlighting the increased risks, particularly in patients with active disease, corticosteroid treatment, and post-surgery. It emphasizes the need for thromboprophylaxis and further research on the pathophysiology of these complications.

This study explores the long-term risk of developing IBD in AIH patients, identifying smoking as a significant risk factor and showing that while IBD increases cirrhosis prevalence, it does not worsen liver-related complications in AIH patients.

This review explores the relationship between pyoderma gangrenosum and inflammatory bowel disease, focusing on epidemiology, clinical features, and treatment approaches. It emphasizes the need for more research to standardize diagnosis and treatment protocols, especially in light of the growing use of biologics.

This review discusses the extraintestinal manifestations of IBD, focusing on the pathophysiology, prevalence, and associations with treatment. It emphasizes the role of immune system dysfunction, genetics, and microbiome in triggering these manifestations, with implications for clinical management.

This review explores ocular manifestations in IBD, including episcleritis, uveitis, and scleritis, discussing their pathophysiology, epidemiology, and management, with an emphasis on the role of IBD treatments and the impact of the microbiome.

This review updates the current understanding of PSC-IBD, discussing its unique clinical features, the increased risk of malignancies, and the challenges in managing this comorbidity.

This systematic review and meta-analysis examines the incidence and risk factors for paradoxical psoriasis or psoriasiform lesions in IBD patients treated with anti-TNF therapy, providing crucial insights into the dermatological side effects of these commonly prescribed medications.

This study finds that psoriasis is associated with an increased risk of developing inflammatory bowel disease, particularly ulcerative colitis, emphasizing the importance of early gastrointestinal monitoring in psoriasis patients.

This review examines the genetic, immune, and microbiological links between psoriasis and inflammatory bowel disease, focusing on shared pathophysiological mechanisms and treatment strategies.

This review discusses the pathogenesis of ankylosing spondylitis, highlighting the role of Type 17 immune responses, gut microbiome dysbiosis, and metabolic factors in disease development. It also explores therapeutic advancements targeting these pathways.

This article investigates the relationship between ankylosing spondylitis, Crohn’s disease, Klebsiella pneumoniae, and starch consumption, suggesting that high starch intake may trigger the growth of Klebsiella and exacerbate disease symptoms, with potential therapeutic implications for dietary management.

This study provides a comprehensive meta-analysis on the prevalence and bidirectional association between inflammatory bowel disease (IBD) and autoimmune liver disease (AILD), shedding light on the significant overlap between these conditions and their shared pathophysiological mechanisms.

This review explores the pathophysiology, prevalence, and treatment strategies for extraintestinal manifestations (EIMs) in Crohn’s disease and ulcerative colitis, emphasizing the role of immune responses, microbiome alterations, and biologic therapies in managing these systemic conditions.

This study examines the clinical features, risk factors, and treatment outcomes of intra-abdominal abscesses (IA) and intestinal free-wall perforations (IP) in Korean patients with Crohn’s disease, highlighting the role of intestinal stricture and disease behavior in complication development.

This review explores the pathophysiology, risk factors, and management of intestinal strictures in Crohn’s Disease, emphasizing genetic, environmental, and imaging factors, as well as current therapeutic approaches.

This review explores environmental risk factors for Crohn’s disease and ulcerative colitis, highlighting modifiable exposures such as smoking, diet, and early-life antibiotic use, and their impact on disease prevention.